Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GRM5 | P41594 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18661406 | 0.73 | ROCK2 (0.46) | MAPTGRM5ALDH1A1RAB9ANPC1 | |
| SCHEMBL31607389 | 0.73 | ROCK2 (0.46) | MAPTGRM5ALDH1A1RAB9ANPC1 | |
| SCHEMBL5923509 | 0.71 | GAA (0.49) | MAPTKMT2AMEN1GAATP53 | |
| SCHEMBL31607337 | 0.69 | JAK3 (0.37) | GRM5 | |
| SCHEMBL10850245 | 0.68 | MAPT (0.47) | MAPTALDH1A1KMT2AMEN1GAA | |
| SCHEMBL5923186 | 0.68 | RXFP1 (0.49) | MAPTALDH1A1KMT2AMEN1GAA | |
| SCHEMBL14862600 | 0.66 | HDAC1 (0.53) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5923511 | 0.66 | SMN1; SMN2 (0.53) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL15732787 | 0.66 | PIM1 (0.47) | KMT2AMEN1GAASMN1; SMN2LMNA | |
| SCHEMBL5923368 | 0.65 | CRHBP (0.50) | MAPTALDH1A1KMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | claimed |
| WO-2005095345-A2 | HETEROARYL GUANIDINES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | claimed |
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | PIGS, GUCY1A1, GUCY1B1 | MAPT 2982/4885GRM5 3521/4885ALDH1A1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.